Hussman Strategic Advisors, Inc. Jounce Therapeutics, Inc. Transaction History

Hussman Strategic Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 01, 2021	SELL	$5.04 - $8.73 $78,120 - $135,315	-15,500 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$6.58 - $10.66 $101,990 - $165,230	15,500 New	15,500 $105,000
Q1 2021 May 03, 2021	SELL	$6.73 - $13.87 $343,230 - $707,370	-51,000 Closed	0 $0
Q4 2020 Feb 01, 2021	SELL	$6.37 - $10.33 $324,870 - $526,830	-51,000 Reduced 50.0%	51,000 $357,000
Q3 2020 Nov 02, 2020	BUY	$4.58 - $10.95 $467,160 - $1.12 Million	102,000 New	102,000 $832,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Hussman Strategic Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Hussman Strategic Advisors, Inc. with notifications on news.